Summary
HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) is calculated from fasting glucose and fasting insulin to produce a single validated index of insulin resistance. A HOMA-IR above 1.5 indicates insulin resistance; above 2.5, it is clinically significant. It identifies insulin resistance years before HbA1c or fasting glucose become abnormal — making it one of the most valuable early metabolic screening tools.
HOMA-IR uses the mathematical relationship between fasting glucose and insulin to model insulin resistance: higher insulin is required to maintain normal glucose when cells are resistant to insulin’s effects.
The formula is: HOMA-IR = (fasting glucose mmol/L × fasting insulin mU/L) ÷ 22.5. Values below 1.5 indicate normal sensitivity; 1.5–2.5 is borderline; above 2.5 indicates significant insulin resistance; above 5.0 is severe.
HOMA-IR is used in research and clinical practice to monitor the response to lifestyle interventions, medications (metformin, GLP-1 agonists), and dietary changes. It is also a validated prognostic tool — higher HOMA-IR predicts type 2 diabetes, cardiovascular events, PCOS severity, and NAFLD.
What It Is
The Homeostasis Model Assessment (HOMA) was developed by Matthews et al. in 1985 at the Oxford Centre for Diabetes. It uses a mathematical model of glucose-insulin interaction at the level of the liver and pancreatic beta-cell to estimate insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) from a single fasting sample.
HOMA-IR formula: (fasting glucose [mmol/L] × fasting insulin [mU/L]) ÷ 22.5. An insulin-sensitive person will have low fasting insulin for a given glucose — producing a low HOMA-IR. An insulin-resistant person requires high insulin to maintain the same glucose level — producing a high HOMA-IR.
HOMA-IR is not directly measured by the laboratory — it is calculated from the two component tests. Some laboratories provide the calculation automatically; in others, it must be calculated manually or requested explicitly.
Functions
Insulin resistance quantification
Provides a validated numerical index of insulin resistance — more informative than fasting insulin or glucose alone.
Pre-diabetes early warning
HOMA-IR rises significantly before fasting glucose or HbA1c become abnormal, enabling earlier intervention.
Treatment response monitor
Serial HOMA-IR measurements objectively track the impact of weight loss, exercise, dietary changes, or medications on insulin sensitivity.
Metabolic risk stratifier
Elevated HOMA-IR predicts future type 2 diabetes, cardiovascular events, PCOS severity, and NAFLD progression.
Reference Ranges
HOMA-IR (calculated)
Measured in ratio (no units)| Status | Range (ratio (no units)) | What it means |
|---|---|---|
| Insulin sensitive | < 1.5 | Normal insulin sensitivity — cells responding efficiently to insulin. |
| Borderline | 1.5–2.5 | Early insulin resistance — lifestyle intervention recommended. |
| Insulin resistant | 2.5–5.0 | Significant insulin resistance — metabolic intervention required. |
| Severe resistance | > 5.0 | Severe insulin resistance — high risk of type 2 diabetes and cardiovascular complications. |
HOMA-IR cut-offs vary between populations and studies. Most clinical studies use > 2.5 as the threshold for significant insulin resistance in European populations. HOMA-IR is a screening and monitoring tool, not a diagnostic criterion for diabetes.
Symptoms of Imbalance
Insulin resistance (elevated HOMA-IR) is often silent for years — symptoms develop as the metabolic consequences accumulate.
- Low HOMA-IR indicates excellent insulin sensitivity — no symptoms expected
- Central weight gain and abdominal obesity
- Fatigue and post-meal energy crashes
- Carbohydrate and sugar cravings
- Brain fog and difficulty concentrating
- Acanthosis nigricans (dark skin patches at neck, armpits, groin)
- Skin tags
- PCOS features in women: irregular periods, acne, hirsutism
Causes of Imbalance
- Low HOMA-IR reflects healthy insulin sensitivity
- Regular physical activity, healthy weight, and low refined carbohydrate diet
- Visceral obesity — the strongest modifiable driver
- Sedentary lifestyle
- High refined carbohydrate and sugar diet
- Chronic sleep deprivation
- Chronic psychological stress (cortisol-driven insulin resistance)
- PCOS
- Cushing's syndrome
- Non-alcoholic fatty liver disease
FAQs
HOMA-IR = (fasting glucose [mmol/L] × fasting insulin [mU/L]) ÷ 22.5. For example: fasting glucose of 5.2 mmol/L × fasting insulin of 12 mU/L ÷ 22.5 = HOMA-IR of 2.77 — indicating significant insulin resistance. If insulin is reported in pmol/L rather than mU/L, divide by 6 first to convert (1 mU/L = 6 pmol/L).
A HOMA-IR below 1.5 indicates excellent insulin sensitivity. Many researchers and clinicians targeting metabolic health and longevity aim for HOMA-IR < 1.0. Values in the 1.0–1.5 range are considered normal but leave some room for improvement. The most meaningful outcome is a downward trend with lifestyle intervention — even if the absolute value has not yet reached the optimal range.
Yes — and often significantly. Regular aerobic exercise (150 minutes per week) and resistance training both improve insulin sensitivity independently of weight loss. Reducing refined carbohydrates and sugar, improving sleep quality, managing stress, and time-restricted eating all lower HOMA-IR through mechanisms distinct from simple weight reduction. That said, sustained weight loss of 5–10% produces the most dramatic improvements.
HOMA-IR is a validated surrogate index for insulin resistance — it correlates well with the gold-standard euglycaemic-hyperinsulinaemic clamp technique in population studies. It does not capture all aspects of insulin resistance (particularly post-prandial resistance), but it is the most practical clinical tool available from a standard fasting blood test. For most purposes, an elevated HOMA-IR is clinically equivalent to saying ‘significant insulin resistance is present.’
HOMA-IR is validated for use in adults without diabetes or pancreatic disease. It is less reliable at the extremes: in people with very high insulin (due to insulinoma) or very low insulin (type 1 diabetes), the model breaks down. It is also less accurate in people with severe liver disease (where glucose production is impaired) and in those with renal failure. For most otherwise healthy adults concerned about metabolic health, it remains the best available fasting insulin resistance index.
References
- Matthews DR, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. View source
- Bonora E, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diabetes Care. 2000;23(1):57–63. View source
- Tabák AG, et al. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379(9833):2279–2290. View source